Table 3a. Process parameters.

Study	2	3			4	5D	8D		9
Publication	(23)	(24)		(25)	(26)	(27)	(33)		(34)	(35)
Subgroup analysis		L	H				B	F
Diagnostic measures/examinations
Blood pressure measurement (regular)		+	+
Measurement of HbA1c level, creatinine level
Measurement of LDL level/cholesterol level									+
Eye check (annual)		+	+						+	+
Foot check (annual)		+	+				+	+	+	+
Drug therapy
Antidiabetes therapy/insulin										+
Antihypertensive therapy
Guideline conform active ingredient group in hypertension treatment	+
Platelet aggregation inhibitors, coronary dilators (e.g. nitrates, molsidomine)	+
Lipid-reducing drugs/statins	+
Statins named in guidelines	+
Drug prescriptions (DDD)
Drug prescriptions (DDD) per 1000 insurance years						+
Counseling on measures to change lifestyle
Healthy nutrition									+	+
Physical activity									+	+
Doctor contacts
Treating physician*		+	+				+
Coordinating physician (≥4 contacts/year)							+
Ophthalmologist (annual)	+						+
Diabetes specialist (≥1 contact/year)

Abbreviations and notes: +: Significant positive difference for DMP groups; –: Significant positive difference for non-DMP groups; Dark blue: p<0.001, mid-blue: p<0.01, pale blue: p<0.05, pale gray: difference not significant; gray: investigated, no significance test performed or no information on statistical significance;

L: Low level of education; H: High level of education; B: Baseline; F: Follow-up; DDD: defined daily dose

^*More frequent treatment by diabetes specialists in DMP groups is evaluated as a positive effect